Electromed (NSDQ:ELMD) CEO Robert Hansen said the company expects its sales and earnings numbers to slide for the 2nd quarter and 2nd half of 2012, after a sales force restructuring hit its top line.
Cambridge Heart Inc.
Covidien (NYSE:COV) beat Wall Street’s earnings expectations for both its fourth quarter and 2011 fiscal year, sending shares up 1.8 percent today.
The Mansfield, Mass.-based health care giant’s medical device segment once again led the charge, posting an 18 percent sales increase for Q4 and 17 percent for the full year.
Cambridge Heart Inc. (OTC:CAMH) saw a sudden uptick in placement orders for its Microvolt T-Wave Alternans (MTWA) OEM module after launching a marketing promotion with Cardiac Science.
Since the beginning of the OEM module promotion in late July to the end of the quarter in September, the Tewksbury, Mass.-based company shipped 45 OEM modules for Cardiac Science’s Q-Stress system, compared to only 13 for the nine months prior to the promotion.
TEWKSBURY, Mass.–(BUSINESS WIRE)–Cambridge Heart, Inc. (OTCBB: CAMH), a developer of non-invasive diagnostic tests for cardiac disease, today announced that the marketing promotion it launched with its OEM partner, Cardiac Science, in July 2011 has yielded an initial increase in placements of its Microvolt T-Wave Alternans™ (MTWA) OEM Module. Since the implementation of the promotion in late July through the quarter ended September 30th 2011, 45 OEM Modules were shipped to purchasers of Cardiac Science’s Q-Stress system, compared with 13 units shipped in the preceding nine months…..
Cambridge Heart (OTC:CAMH) is halting a pilot study and gearing up for a prospective trial to test its MTWA heart-attack test for detecting ischemic events.
The Tewksbury, Mass.-based company’s Microvolt T-Wave Alternans test is currently approved in the U.S. for detecting the risk of heart attack, or arrhythmia, president and CEO Ali Haghighi-Mood told MassDevice. The new trial will investigate whether the test can also predict ischemic events involving restricted blood flow to the heart.
Cambridge Heart Inc. (OTC:CAMH) plans to bring its HearTwave II Microvolt T-Wave Alternans (MTWA) test for sudden cardiac arrest to Singapore through an exclusive distribution deal with EO Medical Pte Ltd.
The deal hinges on the MTWA device winning regulatory approval in Singapore, which the Tewksbury, Mass.-based company expects within the next 6 to 9 months.
Medtronic Inc. (NYSE:MDT) won 510(k) clearance from the FDA for a pedicle screw designed to treat adolescent idiopathic scoliosis.
The Twin Cities medical device colossus said the FDA’s Center for Devices & Radiological Health gave the nod to its TSRH Spiral system pedicle screw. It’s the second Medtronic AIS treatment to land FDA clearance.
AIS is the most common pediatric spine condition, affecting nearly one million U.S. adolescents, according to the company.
TEWKSBURY, Mass.–(BUSINESS WIRE)–Cambridge Heart, Inc. (OTCBB: CAMH), a developer of non-invasive diagnostic tests for cardiac disease, today announced that its HearTwave II System was cleared for sale by the Mexican regulatory authorities. In August 2010, the Company executed an exclusive distribution agreement with Mayerick S.A. de S.V. to distribute the HearTwave II System, including the Company’s proprietary Microvolt T-Wave Alternans™ (MTWA) software and Micro-V Alternans Sensors.
Cambridge Heart Inc. (OTC:CAMH) got a much needed reimbursement win for its Microvolt T-Wave Alternans (MTWA) test for sudden cardiac arrest.
The Tewksbury, Mass.-based cardiac test maker said UnitedHealthcare will make the test a covered benefit for its subscribers. The health insurer is an operating division of UnitedHealth Group, the largest single health carrier in the U.S.
Cambridge Heart Inc. (OTC:CAMH) took a hit during the first quarter, as last year’s acquisition of partner Cardiac Science helped drive sales down 3.2 percent, even as it prepped an offering to raise enough cash to keep going after the end of this year.
Here’s a roundup of companies announcing news at the 2011 Scientific Sessions for the Society for Cardiovascular Angiography and Interventions (SCAI) and Heart Rhythm Society (HRS).